Dulaglutide side effects and risks

Reported side effects

• Nausea: 0.75/1.5 mg: 12.4/21.1%; placebo 5.3%., moderate. Review persistent symptoms before increasing the dose; vomiting may cause dehydration. (source)
• Diarrhea: 0.75/1.5 mg: 8.9/12.6%; placebo 6.7%., moderate. Review persistent symptoms before increasing the dose; vomiting may cause dehydration. (source)
• Vomiting: 0.75/1.5 mg: 6.0/12.7%; placebo 2.3%., moderate. Review persistent symptoms before increasing the dose; vomiting may cause dehydration. (source)
• Abdominal pain: 0.75/1.5 mg: 6.5/9.4%; placebo 4.9%., moderate. Review persistent symptoms before increasing the dose; vomiting may cause dehydration. (source)
• Pancreatitis: In the high dose study: 1.5 mg 0.2%, 3 mg 0.3%, 4.5 mg 0.5%; rare severe cases reported., serious (source)
• Diabetic eye complications: REWIND: 1.9% versus placebo 1.5%; with prior retinopathy, 8.5% versus 6.2%., serious. Monitor existing diabetic retinopathy, especially during rapid glucose improvement. (source)
• Gallbladder disease: REWIND gallstones: 0.62 versus 0.56 events/100 patient years, adjusted for prior gallbladder removal., serious (source)
• Low blood sugar with insulin or sulfonylureas: AWARD 9 with basal insulin: 7.69 versus placebo 8.56 events/patient/year; one severe episode with dulaglutide., serious (source)
• Kidney injury from dehydration: Postmarketing cases, sometimes requiring dialysis; no reliable frequency., serious (source)
• Severe allergic reaction: Anaphylaxis and angioedema are reported; no reliable frequency., serious (source)
• Thyroid C-cell tumors: Rodent finding; whether dulaglutide causes these tumors in humans is unknown., serious (source)

Stop and get help if

• Severe, persistent belly pain, especially spreading to the back: Stop the drug and seek urgent care for possible pancreatitis.
• Face or throat swelling, trouble breathing, or collapse: Call emergency services now; do not take another dose.
• Confusion, seizure, fainting or low blood sugar that does not resolve: Get emergency care. If awake and able to swallow, use fast sugar while help is arranged.
• Repeated vomiting, inability to keep fluids down, or very little urine: Seek urgent assessment for dehydration and kidney injury.
• Upper-right belly pain with fever, yellow skin or pale stools: Seek urgent care for possible gallbladder or bile-duct disease.
• Sudden vision loss or a major new change in vision: Get urgent same-day eye or emergency assessment.
• Chest pain, marked breathlessness or fainting: Call emergency services now.

Who should avoid it

• pregnant: Weight loss is unsuitable; fetal-risk data are limited and animal findings raise concern.
• tryingToConceive: Review a stopping plan before conception; no safe conception interval was established in the extracted sources.
• breastfeeding: Human milk and infant-safety data are inadequate.
• under18: Some labeled diabetes or obesity uses include children; this is not a blanket pediatric label ban.
• mtcOrMen2: Personal or family medullary thyroid cancer or MEN2 is a label contraindication for this GLP-1 product.
• other: Do not re-expose after a serious allergic reaction to the drug or its ingredients.
• pancreatitisHistory: Past pancreatitis needs review; stop and urgently assess persistent severe abdominal pain.
• gallbladderDisease: Gallstones or previous gallbladder inflammation increase the need to assess new upper-abdominal pain.
• gastroparesis: Severe gastroparesis is a label reason to avoid use; these medicines further slow stomach emptying.
• eatingDisorderHistory: Listed as a reason to avoid it.
• kidneyDisease: Kidney function and hydration need review, especially with vomiting or diarrhea.
• liverDisease: Clinical experience in severe liver impairment is limited; review the specific product and other medicines.
• diabeticRetinopathy: Rapid glucose improvement can temporarily worsen diabetic eye disease; arrange appropriate eye follow-up.
• surgeryPlanned: Tell the anesthesia team. Delayed stomach emptying can leave food in the stomach despite fasting.
• diabetes: Review glucose monitoring and insulin or sulfonylurea doses. Do not rapidly stop insulin.

Interactions

• Insulin: Low blood sugar risk can rise. Insulin adjustment needs glucose readings; rapid withdrawal can cause ketoacidosis.
• Sulfonylureas and related insulin-releasing drugs: Low blood sugar can increase; a clinician may need to lower the companion drug dose.
• Another GLP-1 or GLP-1/GIP medicine: Avoid duplicate incretin therapy. Switching guidance stops the previous product rather than stacking both.
• DPP-4 inhibitors: Routine combination is not recommended because it adds little glucose benefit over GLP-1 therapy alone.
• Time-sensitive oral medicines: Slower stomach emptying can alter absorption timing; the effect is medicine-specific. Review critical oral drugs, especially with vomiting or poor intake.
• Warfarin: Monitor INR with initiation or changes; the label advises caution with narrow-therapeutic-index oral drugs.

Product quality risks

• Online GLP-1 products can contain the wrong amount, a different drug or contamination. A seller’s purity claim does not establish sterile injectable quality.
• Three online semaglutide vials had 28.56–38.69% excess drug and endotoxin. Those samples were not this compound.
• No direct laboratory survey of online dulaglutide products was found; semaglutide assay rates cannot be assigned to dulaglutide.